• Current significance and future perspective of 3D-printed bio-based polymers for applications in energy conversion and storage system

  • Back
 by   

Metadata

Document Title

Current significance and future perspective of 3D-printed bio-based polymers for applications in energy conversion and storage system

Author

Putri K.N.A., Intasanta V., Hoven V.P.

Affiliations

Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Center of Excellent for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Maha Chakri Sirindhorn Clinical Research Center (ChulaCRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Center of Excellence in Vaccine Research and Development (Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; School of Global Health, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Department of Microbiology, Faculty of Science, Mahidol University, Bangkok, Thailand; Virology and Cell Technology Research Team, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Pathum Thani, Thailand; Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Clinical Research Laboratory/HIV-NAT Laboratory, ChulaCRC, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Biostatistics Excellence Centre, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Biostatistics Unit, HIVNAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; The Kirby Institute, University of New South Wales, Sydney, Australia; SEARCH Research Foundation, Bangkok, Thailand; Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Genevant Sciences Corporation, Vancouver, BC, Canada; Department of Surgery, Duke University Medical Center, Durham, NC, United States; BioNet Asia, Co. Ltd., Bangkok, Thailand; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States; Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand

Type

Article

Source Title

Scientific Reports

ISSN

20452322

Year

2024

Volume

14

Issue

1

Open Access

All Open Access, Gold

Publisher

Nature Research

DOI

10.1038/s41598-023-49653-6

Abstract

ChulaCov19 mRNA vaccine demonstrated promising phase 1 results. Healthy adults aged 18–59 years were double-blind randomised 4:1 to receive two intramuscular doses of ChulaCov19 50 ?g or placebo. Primary endpoints were safety and microneutralization antibody against-wild-type (Micro-VNT50) at day 50. One hundred fifty adults with median (IQR) age 37 (30–46) years were randomised. ChulaCov19 was well tolerated, and most adverse events were mild to moderate and temporary. Geometric mean titres (GMT) of neutralizing titre against wild-type for ChulaCov19 on day 50 were 1367 IU/mL. T-cell IFN-?-ELISpot showed the highest responses at one week (Day29) after dose 2 then gradually declined. ChulaCov19 50 ?g is well tolerated and elicited high neutralizing antibodies and strong T-cell responses in healthy adults. Trial registration number: ClinicalTrials.gov Identifier NCT04566276, 28/09/2020. ? 2024, The Author(s).

License

CC BY

Rights

Authors

Publication Source

WoS

Continue browsing